Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (“Fuhong Hanlin”) recently received approval from the State Drug Administration to independently develop HLX53 (that is, FC fusion protein to fight Tigit) in combination with the Hans form(i.e. slulizumab injection) and hambetai(i.e. bevacizumab injection) approval to conduct clinical trials for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) (the “Treatment Plan”).